Maze Therapeutics, Inc. priced its initial public offering at $16.00 a share, offering 8,750,000 shares of common stock, to list on the Nasdaq Global Market under the symbol MAZE. It filed a Form S-1 registration statement for an initial public offering on January 7, 2025. As of November 6, 2026, its final prospectus is on file (Form 424B4, January 31, 2025).
Who owns Maze Therapeutics, Inc.?
Sell to companies like Maze Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
Maze Therapeutics, Inc. filed a Form S-1 registration statement for an initial public offering on 2025-01-07. It has amended it 2 times. It filed its final prospectus on 2025-01-31, at a public offering price of $16.00 per share. Each fact below is quoted from the filing named with it.
Also on the record for Maze Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 17, 2026 | Leadership change: Paula A. Johnson appointed, Director, and 1 more | — | Leadership changes | Source |
| August 14, 2026 | Stake report, Schedule 13G/A, by Paradigm BioCapital Advisors LP | — | 5%+ stakes | Source |
| July 29, 2026 | Stake report, Schedule 13G, by BlackRock, Inc. | 5.4% of the class | 5%+ stakes | Source |
| May 22, 2026 | Leadership change: Amy Bachrodt departs, Senior Vice President, Finance | — | Leadership changes | Source |
| May 15, 2026 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 5.8% of the class | 5%+ stakes | Source |
| April 1, 2026 | Stake report, Schedule 13G, by Paradigm BioCapital Advisors LP | 6.1% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Frazier Life Sciences Public Fund, L.P. | 9% of the class | 5%+ stakes | Source |
| February 13, 2026 | Stake report, Schedule 13G/A, by Third Rock Ventures IV, L.P. | 9.3% of the class | 5%+ stakes | Source |
| February 6, 2026 | Stake report, Schedule 13G/A, by Alphabet Holdings LLC | 2.9% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by James Tananbaum | 1.4% of the class | 5%+ stakes | Source |
| November 14, 2025 | Stake report, Schedule 13G/A, by JANUS HENDERSON GROUP PLC | 7.3% of the class | 5%+ stakes | Source |
| November 13, 2025 | Stake report, Schedule 13G/A, by Matrix Capital Management Company, LP | 3.5% of the class | 5%+ stakes | Source |
Check before you invest in Maze Therapeutics, Inc.: the warning signs and who's behind it, free.
Free to see. No signup.
Keep reading
More on Maze Therapeutics, Inc. and the records around it.
Maze Therapeutics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- 5%+ stake filings Aug 2026
- Who owns it
Companies that share a holder
- Third Rock Ventures IV, L.P. also filed stake reports on 1 other company: Tango Therapeutics, Inc. (Feb 2026)
- Foresite Capital Fund IV, L.P. also filed stake reports on 2 other companies: Lyell Immunopharma, Inc. (Aug 2026), Eikon Therapeutics, Inc. (Feb 2026)
- GV 2019, L.P. also filed stake reports on 2 other companies: Ethos Technologies Inc. (Nov 2026), Prime Medicine, Inc. (Nov 2025)
Watch Maze Therapeutics, Inc.
Get an email when Maze Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Maze Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Maze Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Maze Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
17 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
The newest 12 of 15 records.
What the filings say
Listing
Our common stock is listed on The Nasdaq Global Market under the symbol “MAZE.”From the S-1 filed 2025-10-17
Shares offered
We are offering 8,750,000 shares of our common stock.From the 424B4 filed 2025-01-31
Offering price
The initial public offering price is $16.00 per share.From the 424B4 filed 2025-01-31
Use of proceeds
We intend to use the net proceeds from this offering, together with our existing cash and cash equivalents, to fund the clinical development of MZE829, MZE782 and our other discovery and preclinical programs, to conduct research, to broaden the pipeline of product candidates, to fund the further development of our Compass platform, and for working capital and other general corporate purposes.From the 424B4 filed 2025-01-31
Revenue
We may continue to be a SRC after this offering if either (i) the market value of our capital stock held by non-affiliates is less than $250.0 million or (ii) our annual revenue was less than $100.0 million during our most recently completed fiscal year and the market value of our capital stock held by non-affiliates is less than $700.0 million.From the S-1/A filed 2025-01-30
Net loss or income
For the years ended December 31, 2022 and 2023, we incurred a net loss of $114.9 million and $100.4 million, respectively.From the S-1/A filed 2025-01-30
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2025-01-07 | Registration statement filed | S-1 |
| 2025-01-27 | Registration statement amended | S-1/A |
| 2025-01-30 | Registration statement amended | S-1/A |
| 2025-01-31 | Final prospectus filed: the offering is priced | 424B4 |
| 2025-10-17 | Registration statement filed | S-1 |
Tools for this story
Each opens in a new tab, filled in for Maze Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.